Moonlake Immunotherapeutics Announces That 12-week Phase 2 MIRA Trial Data For The Nanobody Sonelokimab In Hidradenitis Suppurativa Will Be Presented At The European Academy Of Dermatology And Venereology Congress
Portfolio Pulse from Benzinga Newsdesk
Moonlake Immunotherapeutics has announced that the 12-week Phase 2 MIRA trial data for the nanobody Sonelokimab in Hidradenitis Suppurativa will be presented at the European Academy of Dermatology and Venereology Congress.
October 04, 2023 | 11:23 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moonlake Immunotherapeutics' announcement of the presentation of the 12-week Phase 2 MIRA trial data for Sonelokimab could potentially impact the company's stock positively.
The announcement of the presentation of the 12-week Phase 2 MIRA trial data for Sonelokimab at a prestigious congress could be seen as a positive development for the company. This could potentially lead to increased investor confidence and a positive impact on the company's stock.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100